STOCK TITAN

Mainz Biomed N.V. - MYNZ STOCK NEWS

Welcome to our dedicated news page for Mainz Biomed N.V. (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mainz Biomed N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mainz Biomed N.V.'s position in the market.

Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) partners with Hermann Bantleon GmbH to offer ColoAlert® At-Home Screening Test to employees across all three German locations in Q1 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) actively participates in two significant gastroenterology conferences in Poland alongside TestDNA, showcasing their flagship product ColoAlert® for colorectal cancer detection and emphasizing the need for earlier detection strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announced groundbreaking results from its eAArly DETECT U.S. clinical study, reporting a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%. The study supports the inclusion of novel mRNA biomarkers in a pivotal FDA clinical trial, positioning the next generation ColoAlert® as a robust and accurate at-home CRC diagnostic screening test on the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.53%
Tags
clinical trial
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present at the 35th Annual Piper Sandler Healthcare Conference. The presentation by CEO Guido Baechler and CFO Bill Caragol will be available for live viewing and post-event webcast. The conference aims to bring together industry executives, investors, and professionals to explore critical trends and identify impactful leaders in the healthcare market. Baechler and Caragol will also be available for 1-on-1 meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announces that its CEO and CFO will present at the 35th Annual Piper Sandler Healthcare Conference in New York, NY, USA. The conference aims to bring together industry executives, investors, and professionals to explore critical healthcare trends. Mainz Biomed's presentation is scheduled for November 29th at 8.50am ET, with opportunities for 1-on-1 meetings with investors throughout the day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
conferences
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) reported a 102% increase in ColoAlert® revenue for the nine months ended September 30, 2023. The company also achieved groundbreaking clinical trial results for ColoFuture study, expanded its network of international commercial partners, and continued preparations for ReconAAsense clinical study. Financially, the company experienced a growth in revenue but an increase in operating loss due to higher sales and marketing and R&D costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
earnings
Rhea-AI Summary
Mainz Biomed N.V. (Nasdaq: MYNZ) announced the closing of a $5.0 million registered direct offering with institutional investors to purchase ordinary shares and warrants. The offering was made pursuant to an effective shelf registration statement on Form F-3 declared effective by the SEC. Titan Partners Group, a division of American Capital Partners, acted as the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
offering
-
Rhea-AI Summary
Mainz Biomed N.V. (MYNZ) Announces $5.0 Million Registered Direct Offering to Institutional Investors for Molecular Genetics Diagnostic Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.43%
Tags
offering
-
Rhea-AI Summary
Mainz Biomed NV (NASDAQ:MYNZ) announced a strategic partnership with Liquid Biosciences to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing. The collaboration aims to extend the use of EMERGE to analyze the Company’s ColoFuture study, integrate novel gene expression biomarkers into ColoAlert®, and advance a self-administered CRC screening tool. Liquid Biosciences is widely considered a premier analytical partner to the life sciences industry, and EMERGE's key attributes include computational speed, ability to handle millions of variables, and unbiased methodology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.14%
Tags
partnership AI
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announced that their VP Commercial Operations, Tarrin Khairi-Taraki, will attend MEDICA, a large medical B2B trade fair, to showcase ColoAlert®, the company's flagship product for at-home detection of colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.45%
Tags
none
Mainz Biomed N.V.

Nasdaq:MYNZ

MYNZ Rankings

MYNZ Stock Data

20.16M
14.78M
17.83%
1.14%
1.71%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Mainz

About MYNZ

mainz biomed is aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. we develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. visit our website www.mainzbiomed.com to learn more about our company and our mission to save lives through science.